LEXX - Lexaria Bioscience Corp Forward P/S Multiple
Precise transportation of compounds for clinical trials ensures therapy safety, which is reflected in the price action of Lexaria Bioscience (LEXX). The company's forward P/S ratio demonstrates the impact of raw material procurement optimization on operating profit. The seamless shipment of small samples for licensing supports stability, while the value of 46.80 serves as the current indicator for this metric, linking market capitalization to expected revenue.
Comprehensive metric breakdowns and analytics for lexariabioscience.com (LEXX)
- market price and analyst price targets:
- market capitalization statistics:
- issuer book value statistics:
- debt and liquidity data:
Debt to Equity Lexaria Bioscience|LEXX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Lexaria Bioscience Corp.|LEXX - Company Total Debt Obligations|Debts to Book Capitalization Lexaria Bioscience Corp.|LEXX - Company Long-Term Debts|Company Current Liabilities Lexaria Bioscience|Quick Ratio lexariabioscience.com
- net income and valuation multiples indicators:
LEXX - Company Net Income|Projected Future Earnings Lexaria Bioscience|LEXX - Business Payback Period|Future Price to Earnings Lexaria Bioscience Corp.|LEXX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexaria Bioscience Corp.|LEXX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Lexaria Bioscience|LEXX - Net earnings per share for the last 12 months|Quarterly EPS earnings growth lexariabioscience.com|LEXX - Expected net earnings per share growth this year|Earnings growth forecast for next year Lexaria Bioscience
- sales and revenue indicators:
Comprehensive company analysis:Lexaria LEXX
Lexaria Bioscience is developing DehydraTECH technology while facing volatility in licensing revenues and fierce competition within the drug delivery sector. The market capitalization to expected revenue ratio, equal to 46.80, measures the premium for future growth, allowing investors to use the forward P/S parameter to filter out random market fluctuations and assess the fair value of the business relative to its potential sales.
Competitors of Lexaria Bioscience
Price-to-Projected Revenue Ratio Haleon HLN|Kenvue Inc - Price-to-Projected Revenue Ratio|Verona Pharma Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Jyong Bio|LGND (Ligand Pharmaceuticals) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue AMRX|PRGO (Perrigo) - Forward P/S Multiple|Forward P/S Multiple Alvotech S.A.|Price-to-Projected Revenue Ratio Liquidia Technologies (LQDA)|GLPG (Galapagos Corp) - Forward Price to Sales|Forward P/S Multiple ANIP (ANI Pharmaceuticals)|Market Cap to Expected Sales Ratio mannkindcorp.com (MNKD)|Amphastar Pharmaceuticals, Inc. - Forward P/S Multiple|PCRX - Forward P/S Multiple|SPRY (ARS Pharma) - Forward Price-to-Revenue Multiple|Theravance Corp - Forward Price to Sales|AQST (Aquestive Therapeutics) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SCPH|Forward P/S Multiple TECX|Market Cap to Expected Sales Ratio Tonix Pharma|Price-to-Projected Revenue Ratio China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. (EPRX) - Market Cap to Future Revenue Ratio|BHST - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio invizyne.com EXOZ|ORMP: Forward P/S Multiple|Forward Price-to-Revenue Multiple Entera Bio|HYFT (MindWalk) - Forward P/S Multiple|ABVC BioPharma, Inc (ABVC) - Market Cap to Expected Sales Ratio|Forward P/S Multiple CPIX|QNTM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio FibroGen FGEN|TELO: Market Cap to Projected Revenue|Rani Therapeutics Inc - Forward P/S Multiple|Synergy CHC Corp (SNYR) - Forward Price-to-Revenue Multiple|RLYB: Forward P/S Multiple|Market Cap to Future Revenue Ratio pulmatrix.com (PULM)|Price-to-Projected Revenue Ratio Pheton Holdings Limited|Price-to-Projected Revenue Ratio APM|Forward P/S Multiple LYRA|IBO - Market Cap to Future Revenue Ratio|TNF Pharmaceuticals, Inc. - Forward Price-to-Revenue Multiple|YCBD: Market Cap to Projected Revenue|PRFX: Forward Price-to-Revenue Multiple|CYTO (Altamira Therapeutics) - Market Cap to Projected Revenue|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Future Price to Revenue OPTN (OptiNose Corp)|PIRS (Pieris Pharmaceuticals) - Forward P/S Multiple|PROC: Forward Price to Sales|Forward P/S Multiple PTPI|Forward P/S Multiple Qilian International Holding Group (QLI)|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|Forward Price to Sales TFFP
